A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. [PDF]
PLoS ONE, 2013 BACKGROUND: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea.
Jun Yong Park +8 more
doaj +1 more source
[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]
Clinical Management Issues, 2015 BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs.
Fabio Tarsetti +4 more
doaj +1 more source
Molecules, 2023 Bentysrepinine (Y101) is a novel phenylalanine dipeptide for the treatment of hepatitis B virus. Renal excretion played an important role in the elimination of Y101 and its metabolites, M8 and M9, in healthy Chinese subjects, although the molecular ...
Aijie Zhang +13 more
doaj +1 more source
Continuous entecavir for treatment-naïve Chinese chronic hepatitis B in the real world setting: the six-year results [PDF]
, 2014 This journal suppl. entitled: 2014 DDW AbstractBACKGROUND: There is a paucity of data on uninterrupted entecavir for treatment-naive chronic hepatitis B (CHB) beyond 5 years.
Fung, J +7 more
core +1 more source
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance [PDF]
, 2011 We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log(10) IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations.
Andreoni, M +8 more
core +1 more source
Beni-Suef University Journal of Basic and Applied Sciences, 2022 Background A meta-analysis was made to assess the impact of entecavir comparison with tenofovir disoproxil fumarate as nucleos(t)ide analogue on hepatic cellular carcinoma (HCC). The study had subjects with chronic hepatitis B virus (HBV).
Sara M. Tony +3 more
doaj +1 more source
Evolution of hepatitis B management in kidney transplantation [PDF]
, 2014 published_or_final_versio
Chan, DTM, Yap, YHD
core +1 more source
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? [PDF]
, 2006 The availability of nucleoside analogues has broadened treatment options for chronic hepatitis B virus (HBV ) infection. Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir,
Buster, E.H.C.J. (Erik) +1 more
core +9 more sources
Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic Hepatitis B virus infected patients [PDF]
, 2012 Natural killer (NK) cells play a critical role in innate antiviral immunity, but little is known about the impact of antiviral therapy on the frequency of NK cell subsets.
Chi, X. +12 more
core +3 more sources
Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]
, 2021 Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G +13 more
core +1 more source